Roivant Sciences arrives at its May 29 earnings report with the short thesis visibly retreating and the analyst community moving in one direction: up.
The most striking shift since the last note is the reversal in short positioning. A week ago, SI had climbed to roughly 5.25% of the float as shorts rebuilt with apparent conviction. That move has now largely unwound. Short interest has dropped to 3.9% of the float — down more than 5% on the week — and the ORTEX short score has fallen from 45.1 on May 14 to 40.9 now, erasing most of the spike. Borrow costs remain negligible at 0.41%, and availability is extraordinarily loose at over 6,000%, meaning there is essentially no friction in either direction for the lending market. The short side looks less like a conviction trade and more like a failed attempt to press into earnings.
Options tell a different story from last week's defensive tilt. The put/call ratio has fallen sharply to 0.63, more than one standard deviation below its 20-day average of 0.85 — the most bullish options posture in months. That's a notable contrast to the risk-off tone that prevailed mid-May. The stock has recovered accordingly, up 5.2% on the week to $29.67 after a brief dip on Tuesday, and is up more than 8% over the past month.
The analyst community has been unambiguously constructive. In the days immediately before the print, Guggenheim lifted its target to $36 and Citigroup raised to $42 — both maintaining Buy — while TD Cowen moved to $41. The mean target across the Street now sits at $39.04, implying roughly 32% upside from current levels. Every recent move has been a raise, not a cut. Bulls point to VTAMA's commercial momentum, the cash position reportedly near $4.5 billion, and Phase 3 readout potential for batoclimab in the second half of 2026 as reasons the pipeline valuation remains underappreciated. Bears argue that the non-revenue-generating vant structure means the stock is essentially a series of binary clinical bets priced at a premium that leaves little margin for setbacks.
On the ownership side, one thread bears watching. Co-President Eric Venker sold $7.2 million of stock across two transactions in the past week alone, and CEO Matt Gline sold $8.5 million in April. The 90-day net insider position is technically positive at roughly $68 million in net value — but that figure reflects earlier option exercises, not fresh buying. The recent pattern is executives selling into strength, not accumulating ahead of results. FMR added over 12 million shares in Q1, and FMR's position now exceeds 10% of shares outstanding, which is a significant counterweight to the insider selling. But the two signals don't cancel — they describe different actors with different time horizons.
The print on May 29 is therefore less about whether the pipeline is intact and more about whether the commercial trajectory of VTAMA and the brepocitinib Phase 2 data can justify a stock that has already rallied nearly 50% year-to-date — with executives cashing out at the highs.
See the live data behind this article on ORTEX.
Open ROIV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
